Company Protalex, Inc.

Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.

Number of employees: 2